Search Results for: Pulmonary

5304 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
HSP90AA1 and PPARD heat shock protein 90 alpha family class A member 1 peroxisome proliferator activated receptor delta
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Carnitine metabolism
  • Regulation of pyruvate dehydrogenase (PDH) complex
  • Nuclear Receptor transcription pathway
  • Signaling by Retinoic Acid
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Alvespimycin
  • Alpha-Linolenic Acid
  • Icosapent
  • Troglitazone
  • Valproic Acid
  • Treprostinil
  • Rosiglitazone
  • Sulindac
  • Fenofibrate
  • Pioglitazone
  • Bezafibrate
  • Phthalic Acid
  • Heptyl-Beta-D-Glucopyranoside
  • Oleic Acid
  • (11E)-OCTADEC-11-ENOIC ACID
  • Elafibranor
  • KD3010
  • GW-501516
  • (2S)-2-{3-[({[2-fluoro-4-(trifluoromethyl)phenyl]carbonyl}amino)methyl]-4-methoxybenzyl}butanoic acid
  • 2-({[3-(3,4-dihydroisoquinolin-2(1H)-ylsulfonyl)phenyl]carbonyl}amino)benzoic acid
  • Indeglitazar
  • {4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)propoxy]phenoxy}acetic acid
  • Clinofibrate
  • Glycerin
HSP90AA1 and RPAP3 heat shock protein 90 alpha family class A member 1 RNA polymerase II associated protein 3
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • vRNP Assembly
  • Regulation of actin dynamics for phagocytic cup formation
  • eNOS activation
  • Regulation of PLK1 Activity at G2/M Transition
  • Scavenging by Class F Receptors
  • Scavenging by Class F Receptors
  • HSP90 chaperone cycle for steroid hormone receptors (SHR)
  • HSF1 activation
  • Attenuation phase
  • HSF1-dependent transactivation
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Sema3A PAK dependent Axon repulsion
  • VEGFA-VEGFR2 Pathway
  • VEGFA-VEGFR2 Pathway
  • VEGFR2 mediated vascular permeability
  • Uptake and function of diphtheria toxin
  • PIWI-interacting RNA (piRNA) biogenesis
  • Anchoring of the basal body to the plasma membrane
  • Constitutive Signaling by EGFRvIII
  • Interleukin-4 and Interleukin-13 signaling
  • Neutrophil degranulation
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Downregulation of ERBB2 signaling
  • ESR-mediated signaling
  • Extra-nuclear estrogen signaling
  • Estrogen-dependent gene expression
  • Chaperone Mediated Autophagy
  • Constitutive Signaling by Overexpressed ERBB2
  • Aggrephagy
  • Drug-mediated inhibition of ERBB2 signaling
  • Signaling by ERBB2 KD Mutants
  • Resistance of ERBB2 KD mutants to trastuzumab
  • Resistance of ERBB2 KD mutants to sapitinib
  • Resistance of ERBB2 KD mutants to tesevatinib
  • Resistance of ERBB2 KD mutants to neratinib
  • Resistance of ERBB2 KD mutants to osimertinib
  • Resistance of ERBB2 KD mutants to afatinib
  • Resistance of ERBB2 KD mutants to AEE788
  • Resistance of ERBB2 KD mutants to lapatinib
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Drug resistance in ERBB2 TMD/JMD mutants
  • Rifabutin
  • Nedocromil
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • Geldanamycin
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-2-Fluoro-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • 9-Butyl-8-(3,4,5-Trimethoxybenzyl)-9h-Purin-6-Amine
  • 4-(1,3-Benzodioxol-5-Yl)-5-(5-Ethyl-2,4-Dihydroxyphenyl)-2h-Pyrazole-3-Carboxylic Acid
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9-Pent-9h-Purin-6-Ylamine
  • 9-Butyl-8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9h-Purin-6-Ylamine
  • 4-(1h-Imidazol-4-Yl)-3-(5-Ethyl-2,4-Dihydroxy-Phenyl)-1h-Pyrazole
  • 9-Butyl-8-(3-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(4-Methoxybenzyl)-9h-Purin-6-Amine
  • 9-Butyl-8-(2,5-Dimethoxy-Benzyl)-2-Fluoro-9h-Purin-6-Ylamine
  • Quercetin
  • 8-Benzo[1,3]Dioxol-,5-Ylmethyl-9-Butyl-2-Fluoro-9h-Purin-6-Ylamine
  • 8-(2-Chloro-3,4,5-Trimethoxy-Benzyl)-9-Pent-4-Ylnyl-9h-Purin-6-Ylamine
  • N-[4-(AMINOSULFONYL)BENZYL]-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • Tanespimycin
  • SNX-5422
  • N-(4-ACETYLPHENYL)-5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-1H-PYRAZOLE-4-CARBOXAMIDE
  • 4-CHLORO-6-(4-{4-[4-(METHYLSULFONYL)BENZYL]PIPERAZIN-1-YL}-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-PIPERAZIN-1-YL-1H-PYRAZOLE-3-CARBOXAMIDE
  • 5-(5-chloro-2,4-dihydroxyphenyl)-N-ethyl-4-[4-(morpholin-4-ylmethyl)phenyl]isoxazole-3-carboxamide
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)ISOXAZOLE-3-CARBOXAMIDE
  • 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-N-ethylthieno[2,3-d]pyrimidine-6-carboxamide
  • 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H-PYRAZOL-5-YL)BENZENE-1,3-DIOL
  • (3E)-3-[(phenylamino)methylidene]dihydrofuran-2(3H)-one
  • 6-(3-BROMO-2-NAPHTHYL)-1,3,5-TRIAZINE-2,4-DIAMINE
  • 3-({2-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)ETHYNYL]BENZYL}AMINO)-1,3-OXAZOL-2(3H)-ONE
  • N-[(2-AMINO-6-METHYLPYRIMIDIN-4-YL)METHYL]-3-{[(E)-(2-OXODIHYDROFURAN-3(2H)-YLIDENE)METHYL]AMINO}BENZENESULFONAMIDE
  • 5-(5-CHLORO-2,4-DIHYDROXYPHENYL)-N-ETHYL-4-(4-METHOXYPHENYL)-1H-PYRAZOLE-3-CARBOXAMIDE
  • 4-bromo-6-(6-hydroxy-1,2-benzisoxazol-3-yl)benzene-1,3-diol
  • 4-[4-(2,3-DIHYDRO-1,4-BENZODIOXIN-6-YL)-3-METHYL-1H-PYRAZOL-5-YL]-6-ETHYLBENZENE-1,3-DIOL
  • 4-chloro-6-{5-[(2-morpholin-4-ylethyl)amino]-1,2-benzisoxazol-3-yl}benzene-1,3-diol
  • 8-(6-BROMO-BENZO[1,3]DIOXOL-5-YLSULFANYL)-9-(3-ISOPROPYLAMINO-PROPYL)-ADENINE
  • 4-methyl-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-2-amine
  • (5E,7S)-2-amino-7-(4-fluoro-2-pyridin-3-ylphenyl)-4-methyl-7,8-dihydroquinazolin-5(6H)-one oxime
  • 8-BENZO[1,3]DIOXOL-,5-YLMETHYL-9-BUTYL-9H-
  • 4-{[(2R)-2-(2-methylphenyl)pyrrolidin-1-yl]carbonyl}benzene-1,3-diol
  • 2-(1H-pyrrol-1-ylcarbonyl)benzene-1,3,5-triol
  • 2-[(2-methoxyethyl)amino]-4-(4-oxo-1,2,3,4-tetrahydro-9H-carbazol-9-yl)benzamide
  • 4-(2-methoxyethoxy)-6-methylpyrimidin-2-amine
  • 4-(2,4-dichlorophenyl)-5-phenyldiazenyl-pyrimidin-2-amine
  • 3,6-DIAMINO-5-CYANO-4-(4-ETHOXYPHENYL)THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE
  • 2-AMINO-4-(2,4-DICHLOROPHENYL)-N-ETHYLTHIENO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
  • Copper
  • Alvespimycin
RBPJ and NOTCH1 recombination signal binding protein for immunoglobulin kappa J region notch receptor 1
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Processing in Golgi
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Activated NOTCH1 Transmits Signal to the Nucleus
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Loss of Function of FBXW7 in Cancer and NOTCH1 Signaling
  • Constitutive Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant
  • Constitutive Signaling by NOTCH1 HD Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • Defective LFNG causes SCDO3
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Bicuspid aortic valve
  • Acute lymphoblastic leukemia (ALL) (precursor T lymphoblastic leukemia)
RBPJ and NOTCH2 recombination signal binding protein for immunoglobulin kappa J region notch receptor 2
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • Notch-HLH transcription pathway
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Pre-NOTCH Processing in the Endoplasmic Reticulum
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Processing in Golgi
  • Pre-NOTCH Processing in Golgi
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • NOTCH2 Activation and Transmission of Signal to the Nucleus
  • Notch-HLH transcription pathway
  • Defective LFNG causes SCDO3
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Alagille syndrome
  • Type II diabetes mellitus
  • Hajdu-Cheney syndrome
INPP5D and GAB2 inositol polyphosphate-5-phosphatase D GRB2 associated binding protein 2
  • Synthesis of PIPs at the plasma membrane
  • Synthesis of IP3 and IP4 in the cytosol
  • Downstream TCR signaling
  • PECAM1 interactions
  • Interleukin receptor SHC signaling
  • PI3K Cascade
  • Signaling by SCF-KIT
  • Signaling by cytosolic FGFR1 fusion mutants
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • RET signaling
  • Interleukin-15 signaling
  • Interleukin receptor SHC signaling
  • FLT3 Signaling
  • STAT5 Activation
IREB2 and TERT iron responsive element binding protein 2 telomerase reverse transcriptase
  • Iron uptake and transport
  • Telomere Extension By Telomerase
  • Formation of the beta-catenin:TCF transactivating complex
  • Zidovudine
  • Grn163l
  • Tertomotide
  • Cri du chat syndrome; Cat cry syndrome; Chromosme 5p deletion syndrome
LMNA and SFTPC lamin A/C surfactant protein C
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Surfactant metabolism
  • Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS)
  • Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
  • Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
  • Pulmonary surfactant metabolism dysfunction (SMDP)
LRP1 and ANAPC10 LDL receptor related protein 1 anaphase promoting complex subunit 10
  • Scavenging of heme from plasma
  • Retinoid metabolism and transport
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Antihemophilic factor, human recombinant
  • Tenecteplase
  • Coagulation Factor IX (Recombinant)
  • Coagulation Factor IX Human
LRP1 and MMP15 LDL receptor related protein 1 matrix metallopeptidase 15
  • Scavenging of heme from plasma
  • Retinoid metabolism and transport
  • Collagen degradation
  • Degradation of the extracellular matrix
  • Degradation of the extracellular matrix
  • Activation of Matrix Metalloproteinases
  • Antihemophilic factor, human recombinant
  • Tenecteplase
  • Coagulation Factor IX (Recombinant)
  • Coagulation Factor IX Human
  • Marimastat
LRP1 and PID1 LDL receptor related protein 1 phosphotyrosine interaction domain containing 1
  • Scavenging of heme from plasma
  • Retinoid metabolism and transport
  • Antihemophilic factor, human recombinant
  • Tenecteplase
  • Coagulation Factor IX (Recombinant)
  • Coagulation Factor IX Human
LRP2 and ANAPC10 LDL receptor related protein 2 anaphase promoting complex subunit 10
  • Vitamin D (calciferol) metabolism
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Retinoid metabolism and transport
  • Inactivation of APC/C via direct inhibition of the APC/C complex
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Phosphorylation of the APC/C
  • APC-Cdc20 mediated degradation of Nek2A
  • Separation of Sister Chromatids
  • Senescence-Associated Secretory Phenotype (SASP)
  • CDK-mediated phosphorylation and removal of Cdc6
  • Transcriptional Regulation by VENTX
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Urokinase
  • Insulin Human
  • Insulin Pork
  • Gentamicin
  • Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome
LRP2 and SCGB1A1 LDL receptor related protein 2 secretoglobin family 1A member 1
  • Vitamin D (calciferol) metabolism
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Retinoid metabolism and transport
  • Urokinase
  • Insulin Human
  • Insulin Pork
  • Gentamicin
  • 4,4'-BIS([H]METHYLSULFONYL)-2,2',5,5'-TETRACHLOROBIPHENYL
  • Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome
LRP2 and PLAU LDL receptor related protein 2 plasminogen activator, urokinase
  • Vitamin D (calciferol) metabolism
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • Retinoid metabolism and transport
  • Neutrophil degranulation
  • Dissolution of Fibrin Clot
  • Urokinase
  • Insulin Human
  • Insulin Pork
  • Gentamicin
  • Urokinase
  • Amiloride
  • 2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide
  • 2-(2-Hydroxy-5-Methoxy-Phenyl)-1h-Benzoimidazole-5-Carboxamidine
  • 6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine
  • 2-(2-Hydroxy-Phenyl)-3h-Benzoimidazole-5-Carboxamidine
  • 6-[N-(4-(Aminomethyl)Phenyl)Carbamyl]-2-Naphthalenecarboxamidine
  • 6-[N-(1-Isopropyl-3,4-Dihydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine
  • CRA_10655
  • 6-[N-(4-Ethyl-1,2,3,4-Tetrahydro-6-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine
  • 6-[N-(1-Isopropyl-1,2,3,4-Tetrahydro-7-Isoquinolinyl)Carbamyl]-2-Naphthalenecarboxamidine
  • 7-Methoxy-8-[1-(Methylsulfonyl)-1h-Pyrazol-4-Yl]Naphthalene-2-Carboximidamide
  • 6-[(Z)-Amino(Imino)Methyl]-N-[4-(Aminomethyl)Phenyl]-4-(Pyrimidin-2-Ylamino)-2-Naphthamide
  • Benzamidine
  • 4-Iodobenzo[B]Thiophene-2-Carboxamidine
  • CRA_8696
  • Trans-6-(2-Phenylcyclopropyl)-Naphthalene-2-Carboxamidine
  • 2-Amino-5-Hydroxy-Benzimidazole
  • N-(1-Adamantyl)-N'-(4-Guanidinobenzyl)Urea
  • 6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine
  • Thieno[2,3-B]Pyridine-2-Carboxamidine
  • 8-(Pyrimidin-2-Ylamino)Naphthalene-2-Carboximidamide
  • [2,4,6-Triisopropyl-Phenylsulfonyl-L-[3-Amidino-Phenylalanine]]-Piperazine-N'-Beta-Alanine
  • Fibrinolysin
  • 6-fluoro-2-(2-hydroxy-3-isobutoxy-phenyl)-1H-benzoimidazole-5-carboxamidine
  • 6-FLUORO-2-[2-HYDROXY-3-(2-METHYL-CYCLOHEXYLOXY)-PHENYL]-1H-INDOLE-5-CARBOXAMIDINE
  • N-(4-CARBAMIMIDOYL-3-CHORO-PHENYL)-2-HYDROXY-3-IODO-5-METHYL-BENZAMIDE
  • 6-[(Z)-AMINO(IMINO)METHYL]-N-[3-(CYCLOPENTYLOXY)PHENYL]-2-NAPHTHAMIDE
  • 1-[4-(2-oxo-2-phenylethyl)phenyl]guanidine
  • (2R)-1-(2,6-dimethylphenoxy)propan-2-amine
  • 4-(2-aminoethoxy)-N-(2,5-diethoxyphenyl)-3,5-dimethylbenzamide
  • 4-(2-aminoethoxy)-N-(3-chloro-2-ethoxy-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide
  • 4-(2-AMINOETHOXY)-3,5-DICHLORO-N-[3-(1-METHYLETHOXY)PHENYL]BENZAMIDE
  • 4-(2-aminoethoxy)-N-(3-chloro-5-piperidin-1-ylphenyl)-3,5-dimethylbenzamide
  • Donnai-Barrow syndrome; Faciooculoacousticorenal syndrome
LTBP3 and TGFB2 latent transforming growth factor beta binding protein 3 transforming growth factor beta 2
  • Molecules associated with elastic fibres
  • Platelet degranulation
  • Molecules associated with elastic fibres
  • ECM proteoglycans
  • Tooth agenesis; Hypodontia
  • Graft-versus-host disease
  • Allograft rejection
MAPT and STAU1 microtubule associated protein tau staufen double-stranded RNA binding protein 1
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
MAPT and BRSK2 microtubule associated protein tau BR serine/threonine kinase 2
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
MAPT and PPP1CB microtubule associated protein tau protein phosphatase 1 catalytic subunit beta
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Triglyceride catabolism
  • Downregulation of TGF-beta receptor signaling
  • Regulation of PLK1 Activity at G2/M Transition
  • Circadian Clock
  • RHO GTPases activate PKNs
  • RHO GTPases activate PKNs
  • RHO GTPases activate CIT
  • RHO GTPases Activate ROCKs
  • RHO GTPases activate PAKs
  • RHO GTPases activate PAKs
  • Lansoprazole
  • Astemizole
  • Paclitaxel
  • Docetaxel
  • Amyotrophic lateral sclerosis (ALS); Lou Gehrig's disease
  • Frontotemporal lobar degeneration (FTLD), including: Pick disease of brain; Frontotemporal dementia (FTD); Ubiquitin-positive frontotemporal dementia (UP-FTD); Progressive supranuclear palsy type 1 (PSNP1); Inclusion body myopathy with early-onset paget disease and frontotemporal dementia (IBMPFD); Frontotemporal dementia, chromosome 3-linked (FTD3)
  • Progressive supranuclear palsy (PSP); Steele-Richardson-Olszewski syndrome
MARK1 and TGFB2 microtubule affinity regulating kinase 1 transforming growth factor beta 2
  • Platelet degranulation
  • Molecules associated with elastic fibres
  • ECM proteoglycans
  • Graft-versus-host disease
  • Allograft rejection
MFAP4 and SFTPD microfibril associated protein 4 surfactant protein D
  • Molecules associated with elastic fibres
  • Toll Like Receptor 4 (TLR4) Cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Signal regulatory protein family interactions
  • Surfactant metabolism
  • Regulation of TLR by endogenous ligand
  • Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
  • Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
  • Beta-D-Glucose
CXCL9 and SFTPC C-X-C motif chemokine ligand 9 surfactant protein C
  • Chemokine receptors bind chemokines
  • G alpha (i) signalling events
  • Surfactant metabolism
  • Defective pro-SFTPC causes pulmonary surfactant metabolism dysfunction 2 (SMDP2) and respiratory distress syndrome (RDS)
  • Defective CSF2RB causes pulmonary surfactant metabolism dysfunction 5 (SMDP5)
  • Defective CSF2RA causes pulmonary surfactant metabolism dysfunction 4 (SMDP4)
  • Pulmonary surfactant metabolism dysfunction (SMDP)

Page 4 out of 266 pages